Home › IncellDx Signs Agreement With Bristol-Myers Squibb Related To The Development Of An Assay For A Companion Diagnostic Test
 

Keywords :   


IncellDx Signs Agreement With Bristol-Myers Squibb Related To The Development Of An Assay For A Companion Diagnostic Test

2013-10-30 05:49:33| drugdiscoveryonline News Articles

IncellDx, Inc. announced today that they have entered into an agreement with Bristol-Myers Squibb Company (NYSE:BMY) related to the development of an assay for potential application in a molecular companion diagnostic intended to identify patients likely to benefit from treatment with a Bristol-Myers Squibb drug that is currently under development

Tags: related development test agreement

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.07Tropical Storm Beryl Graphics
05.07Atlantic Tropical Weather Outlook
05.07Tropical Storm Beryl Public Advisory Number 28A
05.07Summary for Tropical Storm Beryl (AT2/AL022024)
05.07Still no sign of herd rebuilding
05.07Eastern North Pacific Tropical Weather Outlook
05.07Tubi and Pluto lead U.S. surge in free streaming
05.07Tubi free streaming service launches in the UK
More »